Drug intelligence / Profile preview

paclitaxel + varlitinib

Development stage: Unknown
Lead developer: ASLAN Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of varlitinib, a pan-HER inhibitor targeting EGFR, HER2, and HER4, and paclitaxel, a microtubule-stabilizing chemotherapy agent. This combination has been studied primarily for EGFR/HER2 co-expressing advanced gastric cancer and HER2-positive metastatic breast cancer. The recommended phase II dose is varlitinib 300 mg twice daily (intermittently dosed as 4 days on, 3 days off) with weekly paclitaxel at 80 mg/m².

Other names: varlitinib and paclitaxelASLAN001 and paclitaxelASLAN-001 and paclitaxelASLAN 001 and paclitaxel

Targets

EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on paclitaxel + varlitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + varlitinib.

Explore the full profile